COVID-19 Vaccines

Global Market Trajectory & Analytics

MCP16937

EXECUTIVE ENGAGEMENTS

POOL

11708
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

3981
Interactions with Platform & by Email

PARTICIPANTS

955
Unique # Participated

VALIDATIONS

96
Responses Validated*

COMPANIES

335
Responses Validated*
* Login for a full stack data experience

DATE

MAY 2021

TABLES

47

PAGES

817

EDITION

1

PRICE

USD 5800

CODE

MCP16937


COMPETITIVE METRICS

COMPANY

D S N T

% *

Acıbadem Üniversitesi Kerem Aydınlar Kampüsü

Login Required

Accelagen Pty Ltd.

Login Required

AchilleS Vaccines Srl

Login Required

Acıbadem Labmed Health Services A.S.

Login Required

Acıbadem Mehmet Ali Aydınlar University

Login Required

AdaptVac

Login Required

ADImmune Corporation

Login Required

AGC Biologics

Login Required

AIVITA Biomedical, Inc.

Login Required

AJ Vaccines

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 335 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Global COVID-19 Vaccines Market to Reach 9.7 Billion Doses by 2025

Global COVID-19 annual vaccine doses estimated at 11 million doses in 2020 will reach 9.7 billion doses by 2027, displaying at a CAGR of 4.8% over the analysis period 2020-2025. In terms of value, the global market is projected to reach US$132.3 billion by the year 2025 up from the US$267 million estimated in the year 2020. Vaccine doses for children under 18 years, also analyzed as part of the report, will record a projected 90.5% CAGR over the analysis period.

Annual Doses in the U.S. to Plateau at 491 Million by 2025, While Africa Will Peak at 1.1 Billion Doses

Annual vaccine doses administered in the U.S. will plateau at 491 million doses by 2025 after peaking at 543 million doses in the year 2023. The country will record 2.1% CAGR for the period 2020 through 2025. China and Rest of Latin America will recorded the highest growth of 8.1% and 8.7% respectively over the said analysis period. Africa will remain the last region to catch up with the vaccine race. With just 823 million annual doses in 2021, the region is projected to record over 1.1 billion annual doses by the year 2025. In terms of value, annual vaccine doses in the U.S. is estimated at US$16 billion in year 2021, while Africa at the other end of scale weighs in at just US$5 billion for the same year. India, the new epicenter of the global pandemic will record the highest annual vaccine doses of 2.2 billion only in the year 2023.

Vaccines Doses for Under 18 Years to Record 90.5% CAGR

Global annual vaccines doses for children under 18 years estimated at 296.6 million doses in the year 2021, will reach a projected 3.5 billion doses by the year 2025, trailing a 90.5% CAGR. Regions with a large base of young population will witness the fastest growth. Middle East, Africa and Asia are all forecast to grow at 120.5%, 145.1% and 96.7% CAGR respectively. In China and India annual doses administered in this demographic cluster will increase from 109 million doses in 2021 to peak at 1.3 billion doses by the year 2025.

SELECT PLAYERS

Moderna, Inc.; Pfizer Inc./BioNTech; AstraZeneca/University of Oxford; Johnson & Johnson; CanSino Biologics, Inc.; China National Pharmaceutical Group Co., Ltd. (Sinopharm); Sinovac Biotech Ltd.; Novavax, Inc.; Inovio Pharmaceuticals; Sanofi/GlaxoSmithKline; Gamaleya Institute

SEGMENTS

» Age Group (18 Years & Above, Under 18 Years)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » India » Rest of Asia-Pacific » Latin America » Brazil » Mexico » Rest of Latin America » Middle East » Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where Is The World Economy Headed in 2021?
EXHIBIT 1: COVID-19 Cases Worldwide by Country: As on May 01, 2021
EXHIBIT 2: COVID-19 Cases in the US by State: As on May 01, 2021
Increased Hospital Admissions and Deaths Characterize Second and Third Wave
EXHIBIT 14: Daily New Confirmed Cases (Per Million) by Select Country
So How Fast Or Slow Are We Moving?
EXHIBIT 3: How Fast the World is Vaccinated Will Determine How Soon the Pandemic Will End: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets
COVID-19 Vaccine Market Analysis in Million Doses by Region: 2020-2025
EXHIBIT 4: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
COVID-19 Vaccine Market Breakdown in Million Doses by Region: 2021 & 2025
EXHIBIT 5: Global Number of Annual COVID-19 Vaccine Doses (In US$ Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets
COVID-19 Vaccine Market Analysis in US$ Million by Region: 2020-2025
EXHIBIT 6: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
COVID-19 Vaccine Market Breakdown of Dollar Sales by Region: 2021 & 2025
Progress on Vaccinations, Why Should Businesses Care?
These are Times When Questions Abound & Answers Are Few
With IMF’s Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish about a Global Economic Comeback.
EXHIBIT 7: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
COVID-19 Infection Leaves Survivors Struggle with Psychological Complications
SECOND AND THIRD COVID-19 WAVES ENGULF VARIOUS REGIONS
Regional Spike in New Cases in US: Is a Fourth Wave of COVID-19 in Near Future
EUROPE
European Nations Ramp up Restrictions as Third Wave of COVID-19 Envelops Continent
Germany Prolongs Lockdown until June, 2021
France: Night Curfew & Regionalized ‘Lockdown Lite’
Greece Lifts Certain Restrictions
Sweden Vows People to Follow Guidelines
Norway: New Restrictions for Easter
Switzerland Prolongs Lockdown Measures
Spain Eases Restrictions
ASIA-PACIFIC
Fresh Wave of COVID-19 Spiraling Out of Control in Asia-Pacific
SOUTH AFRICAN, INDIAN, AND OTHER COVID-19 VIRUS VARIANTS
COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation’ to Pose Vaccine Challenge
Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
Rising Cases in South Africa & Other Countries
California Strain Emerges to be More Contagious and Deadly
Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines?
Mutated COVID-19 Variant Makes Oxford-AstraZeneca Vaccine Rollout to Go Haywire in South Africa
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection
Moderna’s Variant-Specific Vaccine Candidate Ready for Clinical Study
AstraZeneca Plans to Adapt Covid-19 Vaccine against New Emerging Variants
New Research on Antibodies Efficacy against Variants
AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
COVID-19 Vaccine Approval Details
EXHIBIT 9: Production Capacity by Company for Frontrunners in Millions of Doses for 2021
COVID-19 Vaccine Funding Details
Pfizer/BioNTech’s COVID-19 Vaccine Receives World’s First Authorization
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
After UK, Pfizer’s Vaccine Gains Approval from the US and EU
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
Moderna Kick-Starts Inoculation in the US
AstraZeneca’s Vaccine - Third Globally to Obtain Approval
US FDA Clears J&J’s Single Shot Vaccine for Emergency Use
Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Johnson & Johnson's Adenovirus-based COVID-19 Vaccine: Better than Moderna or Pfizer?
Limitations
Russia Commences Mass Vaccination from Mid-December, 2020
Russia’s Sputnik V Receives Approval for People Aged over 60
Chinese Vaccine Development Scenario
China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
Brazilian Authorities Approve Sinovac’s CoronaVac
AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India
Sanofi Starts Trials of Second Vaccine after Disappointing Results of the First Vaccine
2. A REVIEW OF VARIOUS VACCINES UNDER CLINICAL TRIALS
EXHIBIT: COVID-19 VACCINES UNDER DEVELOPMENT
EXHIBIT 11: COVID-19 Vaccine Candidates in Human Clinical Trials
EXHIBIT 12: Vaccines in Pipeline by Technology
EXHIBIT 13: Vaccine Technologies in Pre-Clinical Studies
A Look into the Other Key Vaccine Frontrunners
CanSino Biologics, Inc. (China)
Novavax, Inc. (US)
Sanofi/GlaxoSmithKline (France/UK)
Merck & Co. (US)
MARKET CHALLENGES
Global Vaccine Shortage Threatens to Slow Immunization Pace
Covid-19 Vaccine Reported Side Effects
Women
Youngsters
People with History of Covid-19 Infection
Overcoming/ Avoiding Side Effects
New Virus Strains
Vaccine Roll Out
Vaccine Efficacy and Resistance
Supply Challenges
Logistics Challenges
Distribution Challenges
Resistance to Vaccination
MARKET DYNAMICS
COVID-19 Vaccine Approvals Shifts All Eyes toward Pre-Order and Distribution Statistics
VACCINES FOR KIDS
Kids: A Key to COVID-19 Mitigation Efforts
Some Unanswered Questions
Pediatric Research Demands High Safety Bar
Uncertainty over Long-Term Adverse Events
PMIS Risk among Infected Children Urges Critical Need for COVID-19 Vaccine
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Pfizer-BioNTech Initiates Covid Vaccine Trial for Children below 12 Years (March 2021)
Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
MRNA: A NEW APPROACH TO MEDICINE
mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
RNA Technology: Benefits & Potential for Future Outbreaks
Key Challenges
mRNA Vaccines Could Vanquish COVID-19 and Cancer
Efforts to Target New Application Areas
Nanotechnology-based Approach Ensures Higher Loading of Active Ingredient of COVID-19 Vaccine
Brazil - A Hotbed for COVID-19 Vaccine Trials
Other Important Clinical Trial Locations
Key Challenges
3. GLOBAL MARKET SIZE ANALYSIS
EXHIBIT 7: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
EXHIBIT 8: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
EXHIBIT 9: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025
EXHIBIT 10: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
Influencer Market Insights
World Market Trajectories
COVID-19 VACCINE DEVELOPMENT- A GLOBAL MARKET OVERVIEW
COVID-19 Vaccine Launches to Kick Start Economic Recovery
Global Reported COVID-19 Cases Surpass 100 Million
An Overview of COVID-19 Vaccines Rollout in 2021
COVID-19 Vaccine Approval Details
COVID-19 Vaccine Funding Details
Pfizer and BioNTech’s Covid-19 Vaccine Receives World’s First Authorization
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
Pfizer/BioNTech’s Vaccine Gets US FDA Emergency Use Authorization
EU Approves Pfizer’s Vaccine
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
Moderna Bags Coveted Approval from US FDA for COVID-19 Vaccine
Moderna Kick-Starts Inoculation in the US
First Mover Challenge: Cold Chain Paucity gives Cold Feet to Vaccine Outreach
Slow Pace of Covid-19 Vaccines Adoption
AstraZeneca’s Vaccine Launch to Bring Cheer this New Year
Pfizer/BioNTech vs. Moderna vs. AstraZeneca Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
EXHIBIT 3: Production Capacity by Company for Frontrunners in Millions of Doses for 2021
J&J to Approach US FDA for Approval in Early February, 2021
J&J to Seek EU Approval for Potential Vaccine Rollout in April, 2021
Russia’s Sputnik V Receives Approval for People Aged Over 60 in Russia
Russia Commences Mass Vaccination in Mid-December
Chinese Vaccine Development Scenario
China Awards Conditional Approval to First Covid-19 Vaccine from Sinopharm
Brazilian Authorities Approve Sinovac’s CoronaVac
AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India
BioNTech to Scale Up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Widespread Rollout of Vaccines to Cut Losses
Rampant Preordering by Rich Countries Raises Concerns of Unequal Vaccine Distribution
NEW CONTAGIOUS COVID-19 VARIANT ARRIVES
COVID-19 Variants Worldwide
Scientists Focusing on Newer Strains
Mutations Capable of Increasing Transmissibility of Coronavirus among Humans
Emerging Variants of Coronavirus in UK and South Africa to be Deadlier than the Early Virus, the US Takes Measures to Curb Spread
Work on Booster Vaccine Jab for Fight against the New South African Variant Begins at Moderna, albeit with Caution
4. MARKET DYNAMICS
COVID-19 Vaccine Approvals Come with Formidable Distribution Challenges
Maintaining Storage Temperature
Airfreight Capabilities
Focus on Cold Chain Infrastructure for Temperature-Sensitive Covid-19 Vaccines
United States Harps on Operation Warp Speed
EXHIBIT 11: US GOVERNMENT DEALS WITH VACCINE DEVELOPERS
Europe’s Horizon 2020
UK’s Independent Vaccine Deals
China – Citizens First
COVID-19 Vaccine Frontrunners Sign Vaccine Safety Pledge
FDA Plans to Issue Stricter Guidelines for Granting Emergency Covid-19 Vaccine Approvals
US States to Prepare for Covid-19 Vaccine Distribution
New UN Pledges Poised to Expand Access to Lifesaving Covid-19 Vaccines
VACCINE MANUFACTURING AND PROCUREMENT – A GLOBAL INSIGHT
EXHIBIT 40: Funding Deals for COVID-19 Vaccine R&D
Developed Economies Lead Global Race to Secure COVID-19 Vaccine Supply
Licensing and Partnership Deals Worldwide to Propel Vaccine Production
EXHIBIT 41: COVID-19 Deals Worldwide - January 2020 to January 2021
Reining in Pandemic Necessitates Fair Access to Resources Globally
Vaccine Alliances Ensure Supplies for All
ANTI-VACCINE MOVEMENT POSES SIGNIFICANT THREAT
Role of COVID-19 Disinformation Campaigns in Growing Vaccine Hesitancy
Preventing Anti-Vaxxer Movement from Going Mainstream
COVID-19 VACCINES LOGISTICS MANAGEMENT
Vaccine Delivery and Success - The Big Task Ahead
The Development and Delivery Challenge
Planning Amid Uncertainty
The Need for a New Approach
Building Cold-chain Storage Infrastructure
Hopes Pegged to Universal Vaccines with Enhanced Temperature Stability
Asians Add Vantage
Handling the Skeptical Consumer
Efficient Task Force for Greater Success Rates
The Importance of Site Selection
Workforce Training
Consumer Education
Government’s Role in Vaccine Distribution
Building Cold Chains Crucial for Vaccine Supplies in Africa, Asia and South America
Bracing up Networks to Combat Crisis
Air Freighters up the Game
FIRST RECIPIENTS OF COVID-19 VACCINES
EXHIBIT 42: Total Number of Frontline Healthcare Professionals in the US: 2019
EXHIBIT 43: Occupation with the Highest COVID-19 Risks in the US
EXHIBIT 45: Food Service Employment by Occupation in the US: 2019
EXHIBIT 46: Total Number of Law Enforcement Officers in the US: 2004 to 2020
INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
The Most Extensive Vaccine Program in the History of Mankind Is Upon US & Many Countries Are Still Unprepared for a Challenge of This Magnitude
The Most Extensive Vaccine Program in the History of Mankind Is Upon US & Many Countries Are Still Unprepared for a Challenge of This Magnitude
Fair Distribution of COVID-19 Vaccine
Vaccine Nationalism to Hamper Equitable Distribution of Vaccines
COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
COVAX Inks Additional Deals and Announces Plans for Global Rollout of Covid-19 Vaccines in Early 2021
African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines (September, 2020)
COVAX Advance Market Commitment (AMC)
World Economic Forum to Push COVID-19 Vaccine Production Capability
Pushing Manufacturing Capacity to Fulfil Global Demand
Technology Transfer and Other Payments
KEY VACCINE TECHNOLOGY PLATFORMS
Inactivated Vaccines
Inactivated Vaccine Candidate in Preclinical Development: As on January 15, 2021
Protein-Subunit Vaccines
Protein-Subunit Vaccine Candidate in Clinical Development: As on January 15, 2021
Non-Replicating Viral-Vector
Non-Replicating Viral Vector Vaccine in Preclinical Development: As on January 15, 2021
Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on January 15, 2021
Nucleic Acid Vaccines
RNA Vaccine Candidate in Preclinical Studies: As on January 15, 2021
DNA Vaccine Candidate in Preclinical Studies: As on January 15, 2021
Replicating Bacteria Vector
Live Attenuated Vaccines (LAVs)
Live Attenuated Virus Candidate in Preclinical Studies: As on January 15, 2021
Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on January 15, 2021
Virus-like Particle Vaccines
Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on January 5th, 2021
UNITED STATES
USA Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
CANADA
EXHIBIT 21: Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
Canada Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
JAPAN
EXHIBIT 23: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
Japan Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
CHINA
China Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
EUROPE
Europe Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in Million Doses for Years 2020 through 2025 and % CAGR
Europe 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Volume Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020 & 2025
FRANCE
France Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
GERMANY
Germany Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
ITALY
Italy Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
SPAIN
Spain Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
RUSSIA
Russia Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
ASIA-PACIFIC
Asia-Pacific Recent Past, Current and Future Analysis
Asia-Pacific Market Analysis: Percentage Share
Asia-Pacific Recent Past, Current and Future Analysis
Asia-Pacific by Region (In US$ Million)
Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in Million Doses for Years 2020 through 2025 and % CAGR
Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Volume Sales for India and Rest of Asia-Pacific Markets for Years 2020 & 2025
INDIA
India Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
LATIN AMERICA
Latin America in Million Doses
Latin America Percentage Share
Latin America Dollar Sales
Latin America Percentage Dollar Sales
Latin America Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in Million Doses for Years 2020 through 2025 and % CAGR
Latin America 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Volume Sales for Brazil, Mexico and Rest of Latin America Markets for Years 2020 & 2025
BRAZIL
Brazil Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
MEXICO
Mexico Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
MIDDLE EAST
Middle East Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
AFRICA
Africa Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR
Total Companies Profiled: 335

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com